GSK Reaches Settlement in Class Action Lawsuit Over BOOSTRIX Vaccine Advertising Claims
In a significant development for those affected by misleading advertising practices, GlaxoSmithKline plc (known as GSK plc) and its associated entity, GlaxoSmithKline LLC, have agreed to a settlement concerning a class action lawsuit filed by Lori DeCostanzo. This lawsuit centers on allegations that the advertising campaign for the BOOSTRIX vaccine falsely represented its effectiveness in preventing the transmission of pertussis to others. The campaign in question, titled 'Big Bad Cough', ran between 2015 and 2020 and has come under scrutiny for its claims.
As part of this settlement, financial relief has been proposed for those who can demonstrate eligibility. Specifically, individuals who received the BOOSTRIX vaccine in New York during the period from May 20, 2016, to May 20, 2020, may qualify for compensation. For those who can provide proof of their vaccination, the settlement awards $50. However, individuals without such documentation may still receive a smaller sum of $10.
The crux of the lawsuit lies in the assertion that the advertising was misleading, leading consumers to believe that the vaccine would effectively protect those around them. In response, GSK has maintained its stance of nonliability and has vigorously defended its advertising strategies throughout the proceedings. The settlement does not equate to an admission of guilt from GSK.
Eligible claimants must complete and submit a valid claim form, which can be done online or by mailing a paper application. The deadline for submissions is set for June 8, 2026. Interested parties are encouraged to visit the official website at www.BigBadCoughSettlement.com for comprehensive information about the claims process and further details about the settlement.
Individuals who opt not to participate in this settlement retain the right to pursue separate legal action against GSK concerning the same issues. To preserve this right, they must formally exclude themselves from the settlement by the deadline of May 11, 2026. Additionally, those wishing to voice their opinions regarding the settlement can object or request to appear at a fairness hearing, scheduled for July 2, 2026, at the United States District Court in Central Islip, New York.
This case highlights the importance of truthful advertising in the pharmaceutical industry and the subsequent ramifications when such standards are not met. The proposed compensation aims to address the concerns of those who felt misled by GSK's marketing practices.
For additional inquiries or legal assistance, individuals can reach out through dedicated hotlines or email addresses provided for the settlement process. It is crucial for affected individuals to stay informed about their rights and the developments in this case as the settlement approaches its final approval stage.
In summary, the negotiated settlement provides a measure of reparations to those impacted by the BOOSTRIX vaccine advertising, encouraging transparency and accountability in pharmaceutical marketing practices moving forward.
As part of this settlement, financial relief has been proposed for those who can demonstrate eligibility. Specifically, individuals who received the BOOSTRIX vaccine in New York during the period from May 20, 2016, to May 20, 2020, may qualify for compensation. For those who can provide proof of their vaccination, the settlement awards $50. However, individuals without such documentation may still receive a smaller sum of $10.
The crux of the lawsuit lies in the assertion that the advertising was misleading, leading consumers to believe that the vaccine would effectively protect those around them. In response, GSK has maintained its stance of nonliability and has vigorously defended its advertising strategies throughout the proceedings. The settlement does not equate to an admission of guilt from GSK.
Eligible claimants must complete and submit a valid claim form, which can be done online or by mailing a paper application. The deadline for submissions is set for June 8, 2026. Interested parties are encouraged to visit the official website at www.BigBadCoughSettlement.com for comprehensive information about the claims process and further details about the settlement.
Individuals who opt not to participate in this settlement retain the right to pursue separate legal action against GSK concerning the same issues. To preserve this right, they must formally exclude themselves from the settlement by the deadline of May 11, 2026. Additionally, those wishing to voice their opinions regarding the settlement can object or request to appear at a fairness hearing, scheduled for July 2, 2026, at the United States District Court in Central Islip, New York.
This case highlights the importance of truthful advertising in the pharmaceutical industry and the subsequent ramifications when such standards are not met. The proposed compensation aims to address the concerns of those who felt misled by GSK's marketing practices.
For additional inquiries or legal assistance, individuals can reach out through dedicated hotlines or email addresses provided for the settlement process. It is crucial for affected individuals to stay informed about their rights and the developments in this case as the settlement approaches its final approval stage.
In summary, the negotiated settlement provides a measure of reparations to those impacted by the BOOSTRIX vaccine advertising, encouraging transparency and accountability in pharmaceutical marketing practices moving forward.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.